CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma. [PDF]
PLoS ONE, 2014 Osteosarcoma (OS) is the most common form of malignant bone tumor and is an aggressive malignant neoplasm exhibiting osteoblastic differentiation. Cisplatin is one of the most efficacious antitumor drugs for osteosarcoma patients.
Hsiao-Chi Tsai +3 more
doaj +10 more sources
Understanding cisplatin resistance using cellular models [PDF]
IUBMB Life, 2007 Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, Mary W., Stordal, Britta
core +9 more sources
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Molecular Cancer, 2022 Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhen-duo Shi +18 more
doaj +2 more sources
CRISPR-Cas9 screening identifies ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efficacy [PDF]
Communications BiologyLiver cancer treatment with cisplatin is often hindered by drug resistance. This study aimed to identify key genes associated with cisplatin resistance in liver cancer and develop targeted inhibitors.
Chujiao Hu +8 more
doaj +2 more sources
Cisplatin Resistance: Genetic and Epigenetic Factors Involved
Biomolecules, 2022 Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the ...
Yuliannis Lugones +2 more
doaj +3 more sources
Study on mechanism of action of β-elemene in inhibiting cisplatin resistance in lung cancer through LncRNA LINC00511 [PDF]
Frontiers in PharmacologyBackgroundLung cancer is a leading cause of cancer-related deaths, with cisplatin being a cornerstone of treatment. However, resistance to cisplatin presents a significant challenge.
Xiaoli Deng +6 more
doaj +2 more sources
Long non-coding RNA LINC00346 contributes to cisplatin resistance in nasopharyngeal carcinoma by repressing miR-342-5p [PDF]
Open Biology, 2020 Cisplatin has been used as the first-line chemotherapy to treat advanced nasopharyngeal carcinoma (NPC), while acquired cisplatin resistance resulting from epigenetic regulation is not well understood. The relative expression of LINC00346 was detected in
Zheqing Cui +4 more
doaj +1 more source
PeerJ, 2021 Backgrounds Cancer cell resistance to chemotherapy drugs such as Gemcitabine, Oxaliplatin, Cisplatin, Doxorubicin, and 5-fluorouracil account for the main reason of chemotherapy failure for HCC patients, especially for those with advanced HCC or metastasis patients.
Zuxiong Tang +5 more
openaire +3 more sources
Frontiers in Pharmacology, 2021 Chemoresistance is the major restriction on the clinical use of cisplatin. Aberrant changes in protein glycosylation are closely associated with drug resistance.
Wenjuan Zeng +12 more
doaj +1 more source
HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway [PDF]
PeerJ, 2023 Background Lung adenocarcinoma is one of the most common tumors, and cisplatin is frequently used in treating lung adenocarcinoma patients. This study aimed to look into the roles and mechanisms of HNF4G in cisplatin resistance of lung adenocarcinoma ...
Jiaqi Liang +11 more
doaj +2 more sources